A Phase II, Multicenter, Long-term Extension Study to Compare the Safety and Efficacy of TAK-385 (10, 20, and 40 mg) Following Oral Administration for 12 Weeks or More in the Treatment of Endometriosis

Name: A Phase II, Multicenter, Long-term Extension Study to Compare the Safety and Efficacy of TAK-385 (10, 20, and 40 mg) Following Oral Administration for 12 Weeks or More in the Treatment of Endometriosis
Creator: Vivli
Published: 2025-02-10 13:15:35
License: 暂无描述

DataCite Commons2025-02-10 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00009883/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this study is to compare the long term safety and efficacy of TAK-385, once daily (QD) following continued administration in participants who completed a Phase II dose-finding study.

提供机构：

Vivli

创建时间：

2024-03-14